Individualization of therapy using Mammaprint: from development to the MINDACT Trial
about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersThe MINDACT trial: the first prospective clinical validation of a genomic toolQuantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifenComparison of prognostic gene expression signatures for breast cancerStability of ranked gene lists in large microarray analysis studies.Predictive biomarker validation in practice: lessons from real trials.Equivalence of MammaPrint array types in clinical trials and diagnostics.Towards the integration, annotation and association of historical microarray experiments with RNA-seqDevelopment and validation of a novel platform-independent metastasis signature in human breast cancer.Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Pathway index models for construction of patient-specific risk profilesEffects of sample size on robustness and prediction accuracy of a prognostic gene signature.Clinical utility of microarrays: current status, existing challenges and future outlook.Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge.Genomic advances and their impact on clinical trial designClinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.Incorporate gene signature profiling into routine molecular testing.Personalized chemotherapy selection for breast cancer using gene expression profilesPathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach.Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors.Preoperative indication for systemic therapy extended to patients with early-stage breast cancer using multiparametric 7-tesla breast MRI.Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
P2860
Q22330767-26AA92B2-0847-46EF-B3CC-D89612C1A8D1Q28242008-575E0988-55C9-4757-9E0B-C11507B73600Q28730018-3E863FB1-EFE8-4C2D-86FD-4910CFAF6F83Q33362164-7746350F-EA04-4291-AA25-0083549BEB7AQ33960208-10B9DC4B-9253-4AC4-9DA3-DD28CA0A3D8EQ34110168-E00199A2-A34C-405E-9EA5-30F4F0D70DC7Q34519347-6DA14978-5F9D-463E-9580-9D8850F93F64Q35051525-2880A269-4660-415D-841C-BD8538AE34E5Q35606889-8CB49836-A52D-44DD-B105-69233417BC55Q35913234-8B390A10-D1DE-458E-8790-76DF12A23327Q36673576-F43795C4-636D-438D-86B9-949B0F28B695Q37209400-351309DA-E19D-4E08-B932-64A35EF84FC5Q37214951-7E4A0022-AED7-46EF-A9F8-CC7ADC9191A0Q37262198-2BE06B2B-378D-4038-9F9C-02AE59582D8DQ37279699-C7F70A0A-F323-4F6A-A6AE-CD2F35549029Q37325013-9D730EAA-29AF-425C-945D-EA8B35D1D4CFQ37463855-8D6B4CD7-5B93-4D8D-98ED-9AC8E57632B7Q37679039-5AF04C5E-79BB-4F27-B269-3EE7F2A9480FQ39042186-CFA0FDA6-077A-4728-810E-587E7F00890CQ42253254-6B769967-DC99-461D-9FF1-29174873CFDEQ42364301-F299B1CE-BB02-4115-98A4-DF5A2BF8D5F1Q48353102-73D399BE-98ED-46E8-9B2C-17F2CE574509Q49843589-9847CAFC-8DA1-4AF4-A69C-07F2FE47EF81
P2860
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@ast
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@en
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@nl
type
label
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@ast
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@en
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@nl
prefLabel
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@ast
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@en
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@nl
P2093
P3181
P1476
Individualization of therapy using Mammaprint: from development to the MINDACT Trial
@en
P2093
Emiel J T Rutgers
Laura J Van't Veer
Martine J Piccart-Gebhart
Stella Mook
P304
P3181
P407
P577
2007-05-01T00:00:00Z